Membrane FasL as a Trigger for Pigmentary Glaucoma
Principal Investigator
Meredith Gregory-Ksander, PhD
Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, MA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
G2006054
Acknowledgement
Summary
Pigmentary glaucoma is one of the most common forms of secondary glaucoma. However, the underlying cause remains unclear. The DBA/2J mouse is an animal model of pigmentary glaucoma and provides us with a unique tool to study the causes of pigmentary glaucoma in order to design improved and targeted treatments. Pigmentary glaucoma in DBA/2J mice is caused when the iris starts to breakdown, releasing particles of “pigment”. Cells of the immune system are activated to clear these pigment particles, causing severe inflammation and blockage of the eyes fluid outflow pathway. Two gene defects are known to cause the release of pigmented particles, resulting in glaucoma. However, there are other unknown factors that contribute to pigmentary glaucoma. This research project will identify one of these previously unknown factors. A unique form of a protein that is expressed in the eye only when pigmentary glaucoma develops has been identified. This protein stimulates inflammation and destroys the fluid outflow system. Completion of this project will identify a new and novel target for treating pigmentary glaucoma.
Related Grants
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
National Glaucoma Research
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute